Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 11
Submit an article Journal homepage
450
Views
12
CrossRef citations to date
0
Altmetric
Original Article: Research

Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia

Uri RozovskiDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA; ;Davidoff Cancer Center, Rabin Medical Center, Institute of Hematology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelView further author information
,
David M. HarrisDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA; View further author information
,
Ping LiDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA; View further author information
,
Zhiming LiuDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA; View further author information
,
Preetesh JainDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA; View further author information
,
Alessandra FerrajoliDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA; View further author information
,
Jan BurgerDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA; View further author information
,
Phillip ThompsonDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA; View further author information
,
Nitin JainDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA; View further author information
,
William WierdaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA; View further author information
,
Michael J. KeatingDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA; View further author information
&
Zeev EstrovDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-1623-3613View further author information
ORCID Icon show all
Pages 2686-2691 | Received 05 Sep 2017, Accepted 01 Feb 2018, Published online: 21 Feb 2018

References

  • Chiorazzi N, Hatzi K, Albesiano E. B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens. Ann N Y Acad Sci. 2005;1062:1–12.
  • Heintel D, Kienle D, Shehata M, et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia. 2005;19:1216–1223.
  • Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625–1638.
  • Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639–1647.
  • Rozovski U, Grgurevic S, Bueso-Ramos C, et al. Aberrant LPL expression, driven by STAT3, mediates free fatty acid metabolism in CLL cells. Mol Cancer Res. 2015;13:944–953.
  • Rozovski U, Hazan-Halevy I, Barzilai M, et al. Metabolism pathways in chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57:758–765.
  • Moreno P, Abreu C, Borge M, et al. Lipoprotein lipase expression in unmutated CLL patients is the consequence of a demethylation process induced by the microenvironment. Leukemia. 2013;27:721–725.
  • Abreu C, Moreno P, Palacios F, et al. Methylation status regulates lipoprotein lipase expression in chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:1844–1848.
  • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
  • Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–2437.
  • Ferrajoli A, Faderl S, Van Q, et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 2007;67:11291–11299.
  • Rakhshandehroo M, Knoch B, Muller M, et al. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010;2010:612089.
  • Herman SE, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123:3286–3295.
  • Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol. 2016;12:1381–1392.
  • Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
  • Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl). 2002;80:753–769.
  • Mansouri M, Sevov M, Fahlgren E, et al. Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity. Leuk Res. 2010;34:301–306.
  • Porpaczy E, Tauber S, Bilban M, et al. Lipoprotein lipase in chronic lymphocytic leukaemia – strong biomarker with lack of functional significance. Leuk Res. 2013;37:631–636.
  • Pallasch CP, Schwamb J, Konigs S, et al. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia. 2008;22:585–592.
  • de Rooij MF, Kuil A, Kater AP, et al. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood. 2015;125:2306–2309.
  • Zaitseva L, Murray MY, Shafat MS, et al. Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. Oncotarget. 2014;5:9930–9938.
  • Cheng S, Ma J, Guo A, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28:649–657.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.